KALA Kala Pharmaceuticals Inc.

KALA BIO Settles Approximately $10.6 million of Debt

KALA BIO Settles Approximately $10.6 million of Debt

ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations.

As previously disclosed in the Company’s Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement Agreement with Oxford pursuant to which the Company owed Oxford $2 million to be paid pursuant to the terms of the Settlement Agreement. The Settlement Agreement was negotiated in connection with events of default under the Loan and Security Agreement dated May 4, 2021 (the “Loan Agreement”).

Recently, KALA completed its $2 million payment obligation to Oxford. Effective immediately upon this payment, the Company is pleased to announce that it has settled the Oxford debt obligations of approximately $10.6 million as of December 26, 2025. As a direct result of this $2 million payment, all of the Company’s obligations under both the Settlement Agreement and the underlying Loan Agreement have been fully satisfied and discharged.

“The successful completion of the Oxford settlement represents a watershed moment for KALA BIO,” said David E. Lazar, Chief Executive Officer and Chairman of the Board. “By settling the Company’s debt obligations and increasing stockholders’ equity, we have removed a substantial overhang that was constraining the Company’s strategic flexibility. We are confident in our path forward.”

Also, as of December 30, 2025, the Company, with the Compensation Committee of KALA’s Board of Directors’ approval, granted common stock awards as a material inducement to employment to four individuals hired by KALA, which common stock awards relate to, in the aggregate, 400,000 shares of common stock.

KALA Contact

David Lazar

Chief Executive Officer and Chairman of the Board



EN
05/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kala Pharmaceuticals Inc.

 PRESS RELEASE

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Eval...

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities Engagement will assess KALA’s clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation, today announced the engagement of Dr. Saeid Babaei, PhD, MBA, as Senior Scientific Advisor. Dr. Babaei’s engagement ...

 PRESS RELEASE

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intellige...

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-built agentic AI solution delivered through its Researgency.ai platfo...

 PRESS RELEASE

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Suppor...

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has eng...

 PRESS RELEASE

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying i...

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeti...

 PRESS RELEASE

KALA BIO Announces Strategic Initiative to Deploy and Continue to Deve...

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s controlPlatform-as-a-service model designed to generate recurring revenue by licensing AI capabilities t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch